EATG » Hepatitis

Hepatitis

Eliminating viral hepatitis: time to match visions with action

Viral hepatitis caused an estimated 1·4 million deaths in 2015—similar to tuberculosis and more than either HIV or malaria, yet historically these diseases have received insufficient attention from donors and…

Dynavax announces FDA approval of HEPLISAV-B(TM) for prevention of hepatitis B in adults

First and only two-dose vaccine in United States for prevention of hepatitis B in adults First new hepatitis B vaccine in United States in more than 25 years BERKELEY, CA…

FDA guidance for industry on DAA development for hepatitis C

FDA published a final guidance on Chronic Hepatitis C Virus Infection: Developing Direct-Acting Antiviral Drugs for Treatment. The guidance can be found at https://www.fda.gov/ucm/groups/fdagov-public/@fdagov-drugs-gen/documents/document/ucm225333.pdf This guidance assists sponsors in the…

Promising new drug for hepatitis B tested

Promising new drug for hepatitis B tested at Texas Biomedical Research Institute San Antonio, Texas (November 7, 2017) – Research at the Southwest National Primate Research Center (SNPRC) on the…

ACHIEVE Coalition sends open letter to Romanian MoH

The ACHIEVE Coalition sent this open letter to the Minister of Health of Romania today. The letter, co-signed by EATG as a member of ACHIEVE, calls the Romanian government to…

Worldwide 52 million children living with viral hepatitis

New data presented at this year's World Hepatitis Summit in Sao Paulo, Brazil (1-3 November) show that 52 million children are living with viral hepatitis worldwide, compared to 2.1 million…

Hepatitis C buyers’ clubs grow worldwide as a way to obtain affordable treatment

Hidden amongst the thousands of Facebook pages given over to holiday snaps and gossip are groups of patients who have hepatitis C, a disease that affects more than 70 million…

Australia: Gonorrhoea and syphilis on the rise, HIV stable, and some good news on hepatitis

Australia’s annual report card on STIs and blood-borne viruses finds that gonorrhoea has increased by 63% over the past five years. Gonorrhoea and syphilis diagnoses are increasing in Australia, HIV…

Treating HCV in HIV-coinfection: still a therapeutic dilemma?

All patients with HIV infection should be screened at least once for HCV. In patients with continued risk factors, such as injecting drug use or men who have sex with…

HCV: Miracle cure costs less than a budget airline flight

The revolution in generic drugs means that a 12-week course of drugs to cure hepatitis C can be manufactured for just US$50 - as low as the cost of a…